Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients


Repare Therapeutics Inc RPTX has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500. 

  • RP-3500 is a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for solid tumors with specific synthetic-lethal genomic alterations.
  • The analysis confirmed the recommended phase 2 dose (160mg 3 days/4 days off).
  • Anemia was the most common reported toxicity, with less than 25% of patients experiencing grade 3 toxicities.
  • Related: Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting.
  • A dose modification plan that includes two alternative dosing schedules were established to mitigate the on-target toxicity of anemia and maintain patients on an RP-3500 dosing schedule that targets anti-tumor activity.
  • The Company will present updated clinical data from 120 patients enrolled in the Phase 1/2 TRESR trial in 1H of 2022.
  • Price Action: RPTX shares are down 1.07% at $14.27 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!